Scottsdale-based HonorHealth and Phoenix-based NeoLight LLC are working together to advance technologies and innovation in the newborn care market. Under this new agreement, HonorHealth Research Institute will assess NeoLight’s medical technologies, starting with NeoLight’s portable Skylife phototherapy treatment device used to treat jaundice in newborns.
Category Archives: AZBio News
C-Path and CHDI launch consortium to accelerate development of Huntington’s therapies
The Critical Path Institute (C-Path), together with CHDI Foundation, Inc. (CHDI), today announced the official launch of C-Path’s Huntington’s Disease Regulatory Science Consortium (HD-RSC). In addition to these cofounders, the consortium also includes more than 20 different member organizations, including industry partners, academic institutions, and nonprofit societies. HD-RSC members will work to advance innovation in regulatory science methods, supporting clearer development and regulatory pathways that lead to the approval of Huntington’s disease (HD) therapeutics.
UA Team Focuses on Feeding a Hungry World
The Future of Farming Takes Root
Sustainable agriculture is quickly becoming the wave of the future as global leaders grapple with the question of how to feed a world population approaching 10 billion. At the University of Arizona, researchers are looking up for answers, in the form of vertical farming.
TGen-ASU study identifies molecular response of muscle to different types of exercise
Hundreds of genes are affected; different types of exercises affect unique sets of genes
Exercise in the future could be customized for individuals based on genomics, according to a study by Arizona State University (ASU) and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.Continue reading
bioSyntagma Awarded $200k Phase I NIH SBIR Grant to Advance Development of a Next-Generation Single-Cell Biomarker Discovery Platform
bioSyntagma, LLC, a precision medicine company, has been awarded a nearly $200,000 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop a new platform for mapping multi-omic biomarkers from single-cells in cancer patient biopsies. bioSyntagma’s Principal Scientist, Dmitry Derkach, M.D., Ph.D., is the Principal Investigator for the project. Continue reading
AZBio In the Loop for the Week of March 19, 2018
|
Senate Proclamation Honors Arizona Bioscience Community
On March 15, 2018, the Arizona Senate recognized the work of the members of Arizona’s Bioscience Community with a Senate proclamation. Continue reading
TGen tests ultrasound as way to enhance cancer drug delivery
Sound waves drive drug therapies to cancer cells; minimize toxicity
Castle Biosciences Announces Receipt of New York Laboratory Permit
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that it has received its Clinical Laboratory Permit from the New York State Department of Health, including approval for three clinical tests. The receipt of the New York permit allows patients in that state to benefit from the Company’s DecisionDx®-Melanoma, DecisionDx®-UM and DecisionDx®-PRAME molecular diagnostic tests that provide actionable molecular information to inform patient care decisions.